Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy

Miriam Revera, Lize Van Der Merwe, Marshall Heradien, Althea Goosen, Valerie A. Corfield, Paul A. Brink, Johanna C. Moolman-Smook

Research output: Contribution to journalArticle

Abstract

Aims: The validity of genotype:phenotype correlation studies in human hypertrophic cardiomyopathy (HCM) has recently been questioned, yet animal models and in vitro studies suggest distinct effects for different mutations. The aims of this study were to investigate whether distinct HCM-mutations have different consequences for cardiac structure and function in the absence of the confounding effects of hypertrophy. Methods and results: Individuals aged 20-65 belonging to 21 R92WTNNT2, R403WMYH7, or A797T MYH7 mutation-bearing families were investigated with 2D, M-mode, and Doppler echocardiography. Cardiac structural and functional parameters were compared between prehypertrophic mutation-carriers and their non-carrier family members, with concomitant adjustment for appropriate covariates. Findings were evaluated against existing animal and in vitro functional data. The distinct functional effect of the R92WTNNT mutation was a relative increase in systolic functional parameters, that of the A797TMYH7 mutation was reduced diastolic function, while the R403WMYH7 mutation reduced both systolic and diastolic function. The observed early effects of the R92W TNNT2 mutation mechanistically fit with prolonged force-transients precipitated by increased Ca2+ sensitivity of the thin filament, and that of the MYH7 mutations with local ATP depletion. Conclusion: Evaluation of the impact of the mutations on cardiac structure and function in prehypertrophic mutation-carriers, relative to the baseline norm provided by their non-carrier family members, best recapitulated existing animal and in vitro functional data, while inclusion of mutation-carriers with hypertrophy obscured such findings. The results prompt speculation that timely treatment aimed at ameliorating Ca2+ sensitivity for R92WTNNT2-carriers, and energy depletion for MYH7 mutation-carriers, may offer a plausible approach for preventing progression from a preclinical into a decompensated state.

Original languageEnglish
Pages (from-to)687-694
Number of pages8
JournalCardiovascular Research
Volume77
Issue number4
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Troponin T
Hypertrophic Cardiomyopathy
Myosins
Hypertrophy
Mutation
Doppler Echocardiography
Genetic Association Studies
Echocardiography

Keywords

  • β-myosin
  • Contractile function
  • Hypertrophic cardiomyopathy
  • Mutation
  • Troponin T

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Revera, M., Van Der Merwe, L., Heradien, M., Goosen, A., Corfield, V. A., Brink, P. A., & Moolman-Smook, J. C. (2008). Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovascular Research, 77(4), 687-694. https://doi.org/10.1093/cvr/cvm075

Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. / Revera, Miriam; Van Der Merwe, Lize; Heradien, Marshall; Goosen, Althea; Corfield, Valerie A.; Brink, Paul A.; Moolman-Smook, Johanna C.

In: Cardiovascular Research, Vol. 77, No. 4, 03.2008, p. 687-694.

Research output: Contribution to journalArticle

Revera, M, Van Der Merwe, L, Heradien, M, Goosen, A, Corfield, VA, Brink, PA & Moolman-Smook, JC 2008, 'Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy', Cardiovascular Research, vol. 77, no. 4, pp. 687-694. https://doi.org/10.1093/cvr/cvm075
Revera, Miriam ; Van Der Merwe, Lize ; Heradien, Marshall ; Goosen, Althea ; Corfield, Valerie A. ; Brink, Paul A. ; Moolman-Smook, Johanna C. / Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. In: Cardiovascular Research. 2008 ; Vol. 77, No. 4. pp. 687-694.
@article{5b440037d8734024bc5d4e29895de6ab,
title = "Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy",
abstract = "Aims: The validity of genotype:phenotype correlation studies in human hypertrophic cardiomyopathy (HCM) has recently been questioned, yet animal models and in vitro studies suggest distinct effects for different mutations. The aims of this study were to investigate whether distinct HCM-mutations have different consequences for cardiac structure and function in the absence of the confounding effects of hypertrophy. Methods and results: Individuals aged 20-65 belonging to 21 R92WTNNT2, R403WMYH7, or A797T MYH7 mutation-bearing families were investigated with 2D, M-mode, and Doppler echocardiography. Cardiac structural and functional parameters were compared between prehypertrophic mutation-carriers and their non-carrier family members, with concomitant adjustment for appropriate covariates. Findings were evaluated against existing animal and in vitro functional data. The distinct functional effect of the R92WTNNT mutation was a relative increase in systolic functional parameters, that of the A797TMYH7 mutation was reduced diastolic function, while the R403WMYH7 mutation reduced both systolic and diastolic function. The observed early effects of the R92W TNNT2 mutation mechanistically fit with prolonged force-transients precipitated by increased Ca2+ sensitivity of the thin filament, and that of the MYH7 mutations with local ATP depletion. Conclusion: Evaluation of the impact of the mutations on cardiac structure and function in prehypertrophic mutation-carriers, relative to the baseline norm provided by their non-carrier family members, best recapitulated existing animal and in vitro functional data, while inclusion of mutation-carriers with hypertrophy obscured such findings. The results prompt speculation that timely treatment aimed at ameliorating Ca2+ sensitivity for R92WTNNT2-carriers, and energy depletion for MYH7 mutation-carriers, may offer a plausible approach for preventing progression from a preclinical into a decompensated state.",
keywords = "β-myosin, Contractile function, Hypertrophic cardiomyopathy, Mutation, Troponin T",
author = "Miriam Revera and {Van Der Merwe}, Lize and Marshall Heradien and Althea Goosen and Corfield, {Valerie A.} and Brink, {Paul A.} and Moolman-Smook, {Johanna C.}",
year = "2008",
month = "3",
doi = "10.1093/cvr/cvm075",
language = "English",
volume = "77",
pages = "687--694",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy

AU - Revera, Miriam

AU - Van Der Merwe, Lize

AU - Heradien, Marshall

AU - Goosen, Althea

AU - Corfield, Valerie A.

AU - Brink, Paul A.

AU - Moolman-Smook, Johanna C.

PY - 2008/3

Y1 - 2008/3

N2 - Aims: The validity of genotype:phenotype correlation studies in human hypertrophic cardiomyopathy (HCM) has recently been questioned, yet animal models and in vitro studies suggest distinct effects for different mutations. The aims of this study were to investigate whether distinct HCM-mutations have different consequences for cardiac structure and function in the absence of the confounding effects of hypertrophy. Methods and results: Individuals aged 20-65 belonging to 21 R92WTNNT2, R403WMYH7, or A797T MYH7 mutation-bearing families were investigated with 2D, M-mode, and Doppler echocardiography. Cardiac structural and functional parameters were compared between prehypertrophic mutation-carriers and their non-carrier family members, with concomitant adjustment for appropriate covariates. Findings were evaluated against existing animal and in vitro functional data. The distinct functional effect of the R92WTNNT mutation was a relative increase in systolic functional parameters, that of the A797TMYH7 mutation was reduced diastolic function, while the R403WMYH7 mutation reduced both systolic and diastolic function. The observed early effects of the R92W TNNT2 mutation mechanistically fit with prolonged force-transients precipitated by increased Ca2+ sensitivity of the thin filament, and that of the MYH7 mutations with local ATP depletion. Conclusion: Evaluation of the impact of the mutations on cardiac structure and function in prehypertrophic mutation-carriers, relative to the baseline norm provided by their non-carrier family members, best recapitulated existing animal and in vitro functional data, while inclusion of mutation-carriers with hypertrophy obscured such findings. The results prompt speculation that timely treatment aimed at ameliorating Ca2+ sensitivity for R92WTNNT2-carriers, and energy depletion for MYH7 mutation-carriers, may offer a plausible approach for preventing progression from a preclinical into a decompensated state.

AB - Aims: The validity of genotype:phenotype correlation studies in human hypertrophic cardiomyopathy (HCM) has recently been questioned, yet animal models and in vitro studies suggest distinct effects for different mutations. The aims of this study were to investigate whether distinct HCM-mutations have different consequences for cardiac structure and function in the absence of the confounding effects of hypertrophy. Methods and results: Individuals aged 20-65 belonging to 21 R92WTNNT2, R403WMYH7, or A797T MYH7 mutation-bearing families were investigated with 2D, M-mode, and Doppler echocardiography. Cardiac structural and functional parameters were compared between prehypertrophic mutation-carriers and their non-carrier family members, with concomitant adjustment for appropriate covariates. Findings were evaluated against existing animal and in vitro functional data. The distinct functional effect of the R92WTNNT mutation was a relative increase in systolic functional parameters, that of the A797TMYH7 mutation was reduced diastolic function, while the R403WMYH7 mutation reduced both systolic and diastolic function. The observed early effects of the R92W TNNT2 mutation mechanistically fit with prolonged force-transients precipitated by increased Ca2+ sensitivity of the thin filament, and that of the MYH7 mutations with local ATP depletion. Conclusion: Evaluation of the impact of the mutations on cardiac structure and function in prehypertrophic mutation-carriers, relative to the baseline norm provided by their non-carrier family members, best recapitulated existing animal and in vitro functional data, while inclusion of mutation-carriers with hypertrophy obscured such findings. The results prompt speculation that timely treatment aimed at ameliorating Ca2+ sensitivity for R92WTNNT2-carriers, and energy depletion for MYH7 mutation-carriers, may offer a plausible approach for preventing progression from a preclinical into a decompensated state.

KW - β-myosin

KW - Contractile function

KW - Hypertrophic cardiomyopathy

KW - Mutation

KW - Troponin T

UR - http://www.scopus.com/inward/record.url?scp=39749164101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749164101&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvm075

DO - 10.1093/cvr/cvm075

M3 - Article

C2 - 18029407

AN - SCOPUS:39749164101

VL - 77

SP - 687

EP - 694

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 4

ER -